共 33 条
Magnetic beads-based enzymatic spectrofluorometric assay for rapid and sensitive detection of antibody against ApxIVA of Actinobacillus pleuropneumoniae
被引:31
作者:
Wei, Bo
[1
,2
]
Li, Fang
[1
]
Yang, Huicui
[1
,2
]
Yu, Lei
[1
]
Zhao, Kaihong
[1
,2
]
Zhou, Rui
[1
]
Hu, Yonggang
[1
,2
]
机构:
[1] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China
[2] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan 430070, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Magnetic particles;
Actinobacillus pleuropneumoniae;
Enzymatic amplification;
Fluorescence immunoassay;
INJECTION IMMUNOASSAY;
FLUORESCENCE;
IMMOBILIZATION;
IMMUNOSENSOR;
PATHOGENESIS;
INFECTIONS;
SYSTEMS;
D O I:
10.1016/j.bios.2012.03.027
中图分类号:
Q6 [生物物理学];
学科分类号:
071011 ;
摘要:
In this paper, a simple, easily-operated and enzyme-amplified fluorescence immunoassay method using magnetic particles for the detection of antibody against Actinobacillus pleuropneumoniae (APP) has been presented. The A protein of APP Repeats-in-Toxin IV (ApxIVA) with high specificity to the APP species was immobilized onto the magnetic bead surfaces. Horseradish peroxidase (HRP), which can catalyze the substrate 4-hydroxyphenylacetic acid (p-HPA), generating fluorescent bi-p, p'-hydroxyphenylacetic acid (DBDA), was selected as an enzymatic-amplified tracer. The ApxIVA antibody was detected for the presence of APP infection by measuring the fluorescence intensity of DBDA. Under optimal conditions, the calibration plot obtained for standard positive serum was approximately linear within the dilution range 1:160-1:5120. The limit of detection (LOD) for the assay was 1:10240, considerably lower than that of ApxIVA-ELISA (1:320) (S/N = 3). A series of repeatability measurements of using 1:320-fold diluted standard positive serum gave reproducible results with a relative standard deviation (RSD) of 4.8% (n = 11). The ability of the immunosensor to analyze clinical samples was tested on porcine sera. The immunosensor yielded an efficiency of 89.7%, sensitivity of 90.9% and specificity of 89.3% compared with ApxIVA-ELISA. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:390 / 393
页数:4
相关论文